Search
Nusinersen
go.drugbank.com/drugs/DB13161ApprovedInvestigationalAn antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S. … FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy (SMA). It is adminstrated as direct intrathecal injection.
Rezafungin
go.drugbank.com/drugs/DB16310ApprovedInvestigational[L45633,L45658] It was subsequently approved in the EU in November of the same year. [L52745] … Rezafungin is an echinocandin antifungal drug.
Loncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalZylonta also received approval in the EU on December 22, 2022. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.
Sertindole
go.drugbank.com/drugs/DB06144ApprovedWithdrawnIt was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. … It is a phenylindole derivative used in the treatment of schizophrenia.
Eltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked
gamma-Hydroxybutyric acid
go.drugbank.com/drugs/DB01440ApprovedIllicitInvestigationalIt is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985). … GHB is a naturally occurring substance found in the central nervous system, wine, beef, small citrus fruits and almost all other living creatures in small amounts.
Synonyms: oxy-n-butyric acidEfanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigationalepisodes in patients with hemophilia A. … [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]
Sulbactam
go.drugbank.com/drugs/DB09324ApprovedInvestigational[L50131] When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resistance by hydrolyzing β-lactams.[A263296]
Mixtures: AMPICILLINA E SULBACTAM IBI, AMPICILLINA E SULBACTAM IBIMoroctocog alfa
go.drugbank.com/drugs/DB13999Approvedin the 1980s [A31551, A32272, L2177]. … Bleeding can range in severity from minor concerns, such as nosebleeds, to more serious events such as hemorrhaging in the joints, brain, or digestive tract [A32280].